December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

144.86 +0.70 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth ↗
 
Via Benzinga
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
News headline image
Heska To $165? Plus BTIG Cuts PT On This Stock By 67% ↗
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... 
Via Benzinga
News headline image
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
News headline image
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Looking Into Neurocrine Biosciences's Return On Capital Employed ↗
According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90... 
Via Benzinga
News headline image
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review ↗
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
News headline image
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat ↗
The company raised its guidance for Ingrezza sales in 2022. 
Via Investor's Business Daily
News headline image
Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat? ↗
Neurocrine says the essential tremor drug didn't hit its goals in a key study. 
Via Investor's Business Daily
News headline image
Neurocrine Biosciences: Q3 Earnings Insights ↗
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Earnings Scheduled For November 1, 2022 ↗
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
News headline image
4 Analysts Have This to Say About Neurocrine Biosciences ↗
Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022 ↗
Upgrades 
Via Benzinga
News headline image
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market ↗
Eli Lilly leads medical stocks setting up and showing relative strength. 
Via Investor's Business Daily
News headline image
S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms ↗
Devon Energy leads this weekend's watch list of stocks in a tough market. 
Via Investor's Business Daily
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Neurocrine Leads 5 Stocks To Watch In Sickly Market ↗
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
News headline image
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
News headline image
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points ↗
Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries. 
Via Investor's Business Daily
News headline image
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study ↗
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. 
Via Benzinga
News headline image
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.